Industry: Pharmaceuticals (See others in industry)
Address:| Date | FilingType | Incremental Cash | Link to Raw Filing | |||
|---|---|---|---|---|---|---|
| 2025-10-03 | New | $0 | $0 | Other | 06b | SEC link |
| 2023-04-19 | Amended | $12,780,000 | $4,162,500 | Equity Only | 06b | SEC link |
| 2022-08-05 | New | $8,617,500 | $8,617,500 | Equity Only | 06b | SEC link |
| 2021-02-24 | New | $0 | $0 | Other | 06b | SEC link |
| 2021-01-20 | New | $0 | $0 | Other | 06b | SEC link |
| 2018-08-28 | Amended | $6,600,000 | $600,000 | Equity Only | 06b | SEC link |
| 2018-08-02 | New | $6,000,000 | $6,000,000 | Equity Only | 06b | SEC link |
| 2007-06-05 | Paper Filing | Unknown | Unknown | Other | Not Available |
| Name | Role |
|---|---|
| Dimitrios Angelis | Director |
| Venkatraman Balakrishnan | Director |
| Kevin M. Coveney | Executive |
| Dr. Bob Dagher | Executive |
| Bob Dagher | Executive |
| Sheila De Witt | Director |
| Srinidhi Devanur | Director, Executive |
| Jeffrey Eberwein | Director |
| Peter Facchini | Executive |
| Peter Facchini, Ph D | Executive |
| David Johnson | Director, Executive |
| Avani Kanubaddi | Executive |
| George W. Kegler | Director |
| Brent Kelton | Executive |
| Douglas Lind | Director |
| Dr. Douglas Lind | Director |
| David Luci | Director |
| Sol Mayer | Director |
| Bevin O'neil | Director |
| Bevin O'niel | Director |
| Frank Pasqualone | Director |
| Viraj Patel | Executive |
| Robert Pearse | Director |
| Dr. Marcus Schabacker | Director |
| Marcus Schabacker | Director |
| James Shad | Director |
| Robert Shawah | Director |
| Joseph E. Tucker | Director, Executive |
| Joseph Tucker, Ph D | Director, Executive |
| John Van Buiten | Executive |
| Carter Ward | Executive |
| Michael D. Webb | Director |